Catholicon Pharmaceuticals

Catholicon Pharmaceuticals is a biotechnology company focused on the development of broad-spectrum antiviral therapeutics to address global health threats. The company leverages advanced Human-on-a-Chip microphysiological systems to accelerate the transition of drug candidates from the lab to clinical trials. Their lead research program, CP-001, is a small molecule designed to treat a variety of viral respiratory infections, including COVID-19 and influenza, by targeting conserved host or viral mechanisms. By utilizing human-based models for efficacy testing, Catholicon aims to reduce the reliance on animal testing and improve the predictability of clinical outcomes. The company's approach is specifically designed to maintain effectiveness against emerging viral variants that may evade traditional vaccines.